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Complex, and Hard to Treat
Laura M. Filkins, George A. O’Toole*
Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, New
Hampshire, United States of America
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It’s Not Just aboutHaemophilus influenzae, Staphylococcus
aureus, and Pseudomonas aeruginosa
Historically, H. influenzae and S. aureus were considered to be the primary organisms infecting
the airways of infants and children with CF, followed by P. aeruginosa or Burkholderia cepacia
complex during adulthood. These bacteria continue to play important roles in CF respiratory
infections and clinical outcome; however, with the advent of improved culture methods and
culture-independent approaches, including deep sequencing technology, it is clear that the air-
ways of patients with CF are chronically colonized with complex, polymicrobial infections. In
2003, Rogers and colleagues revolutionized our understanding of CF lung infections through
their identification of complex bacterial communities in sputum and bronchoscopy samples
using a culture-independent, molecular-based approach, terminal restriction fragment length
polymorphism profiling. This study was the first to recognize the role of highly prevalent and
diverse bacterial species previously unrecognized in CF lung infections, including obligate
anaerobes [1]. Since then, several additional studies utilizing culture-independent approaches
have confirmed that the airways of patients with CF are chronically colonized with diverse bac-
terial, fungal, and viral taxa [2–5]. These polymicrobial communities are highly individualized
to each patient and promote intricate inter-microbial and host—pathogen interactions, which
alter the lung environment, impact response to treatment, and direct the course of disease
(summarized in Fig 1).
Core genera, including Streptococcus, Pseudomonas, Prevotella, Veillonella, Neisseria, Por-
phorymonas, and Catonella are detected in abundance in the majority of adult sputum samples
[7]. In addition to this core, deep sequencing typically identifies 50–200 unique operational
taxonomic units in a single CF respiratory sample. Furthermore, the advancement of molecular
identification approaches has greatly enhanced our recognition of the diverse fungi (including
Candida spp.,Malassezia spp., and Aspergillus spp.) and viruses (including influenza and respi-
ratory syncytial virus) that co-inhabit the lungs of patients with CF [2,4,8].
Accompanying the explosion of organisms recognized in these multi-domain communities
comes the task of determining the role of such microbes in CF lung disease. In the recently
accepted context of highly individualized, complex, polymicrobial communities, answering the
question of “who’s the pathogen?” has become a non-trivial challenge of both clinical diagnos-
tic and academic research focus. Emerging pathogens (microbes that directly contribute to dis-
ease progression and poor patient outcome) of interest are bacterial (Streptococcusmilleri
group spp., nontuberculous mycobacterium), fungal (Trichosporon spp.), and viral (rhinovi-
rus). Meanwhile, other organisms previously considered to be pathogenic in the context of CF
lung infections are now more widely thought of as normal microbiota and unlikely pathogens,
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Fig 1. Cystic fibrosis lung infections are polymicrobial, complex, and challenging to treat. The airways of patients with CF are colonized from various
host (as indicated) and environmental (not depicted) sources. Patients subsequently develop chronic, polymicrobial infections composed of diverse bacterial,
fungal, and viral organisms. These polymicrobial communities both influence and are impacted by their human host through complex, multifactorial
interactions. As highlighted in the figure above and throughout this review, CF lung microbial communities encounter frequent antibiotic therapy, host
immune factors, and an altered lung environment (including the presence of hypoxic [low oxygen] and anoxic [no oxygen] regions) throughout disease
progression, all of which contribute to the development of chronic communities that often have decreased microbial diversity and are populated by organisms
that have become highly adapted and resilient to treatment. The combination of diverse colonization sources, dynamic inter-domain interactions, microbial
adaptation, environmental factors, and patient therapy mediates patient outcome. Eventually, chronic pulmonary infection culminates in a decline in lung
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including Stenotrophomonas maltophilia, Achromobacter spp., Ralstonia spp., Burkholderia
gladioli, and Streptococcus pneumoniae [8].
Defining individual organisms as pathogenic (or not) is a convenient tool for standardizing
treatment approaches. However, as we now understand the complexity of these polymicrobial
infections, it is critical to begin interpreting the function and impact of infecting microbes in
the context of their community, not as individuals. To this point, Sibley and colleagues demon-
strated that co-infection of oropharyngeal microbes with P. aeruginosa frequently altered
(strain-dependent increase or decrease) host survival in a Drosophilamodel, compared to
mono-infection of either organism [9].
Furthermore, distinguishing between carriage (not contributing directly to disease) of
microbes versus their role as bona fide pathogens is often unclear. For example, rhinovirus
detection in the upper respiratory tract of infants and children is common and is thought to
typically have minimal impact on the respiratory disease course in this young cohort [10].
However, increased detection of rhinovirus (as well as influenzae A and B viruses) was also
reported during pulmonary exacerbation, compared to periods of stability [11]. A similar dual
role of carriage and pathogenic potential has been described for emerging bacterial pathogens
of the Streptococcusmilleri group and the fungus Candida albicans [8,12–14]. Understanding
the environmental, host, or inter-microbial triggers that lead to the pathogenic role for these
and other microbes is imperative for proactive patient treatment and prevention of disease
worsening.
The Lung Environment Is Not Always Aerobic
Contrary to common intuition, the lungs are not entirely aerobic—especially the airways of
patients with CF. In CF, mutations in the cystic fibrosis transmembrane conductance regulator
gene lead to decreased chloride ion secretion and dehydration of the airway surface liquid
layer, which leads to deficient mucociliary clearance and development of a thick mucus layer.
The combination of thickened mucus and decreased clearance further facilitates the formation
of mucus plugs that can obstruct the airways and form a protected niche for microbes [15].
Within this thick mucus, and particularly within the plugs, a steep oxygen gradient forms with
hypoxic (low oxygen) or anoxic (no oxygen) regions (see Fig 1). Additionally, mucus hypoxia
or anoxia may be further enhanced by oxygen consumption and growth of colonizing organ-
isms, such as P. aeruginosa [16]. The airways of patients with CF are heterogeneous in regard
to the tissue environments (e.g., localized regions of high versus low oxygen and regional
variation in inflammation) and microbial communities (e.g., the abundance of microbes
and composition of communities in different regions of the airway) [17]. This heterogeneity
impacts localized host and microbial interactions and, ultimately, disease progression.
Microbes equipped to survive under diverse host conditions, in particular low or varied oxygen
concentrations, may have increased potential to chronically colonize the airways and impact
patient outcome. Species traditionally thought of as aerobic microbes are often also equipped
to survive and grow in low- or no-oxygen environments. P. aeruginosa, for example, can grow
by respiring nitrate and nitrite in anoxic environments and has multiple terminal oxidases that
support aerobic respiration in low oxygen conditions [18]. P. aeruginosa also has the capability
to ferment arginine and pyruvate to provide maintenance energy [19]. Furthermore, the
function, which becomes most severe during pulmonary exacerbations and late stage disease progression. This steep decline in lung function ultimately
leads to respiratory failure, the primary cause of morbidity and mortality in CF patients today [6]. Figure illustration and design copyright 2015William
Scavone and used with permission.
doi:10.1371/journal.ppat.1005258.g001
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viscous mucous and low-oxygen environments may be advantageous for some species, such as
P. aeruginosa, that experience enhanced antibiotic tolerance under such conditions [19].
Finally, the high prevalence and abundance of anaerobic species in the CF airway provides
empirical evidence for anoxic niches within the lung [1]. These anaerobes are not merely dead
cells transiently inhaled into the lungs; patient lung samples house viable, diverse anaerobic
species that can be recovered in culture [20], and longitudinal microbiome studies have further
shown that these anaerobes are chronic residents [5]. The role of obligate anaerobes and non-
oxygen respiring microbial lifestyles in the development of chronic polymicrobial communities
and disease progression is currently not well understood and is a growing focus in the field.
Who Did It? Lung Infections Are Seeded by Our Mouth, Nose, Skin,
Gut, Siblings, Neighbors, and Dirt
In the absence of predominating P. aeruginosa, oral-associated microbes can be the most prev-
alent and abundant species found in the CF lung. Indeed, microbiome studies indicate that
P. aeruginosamay only be predominant in approximately 50% of adult patients [13]. Impor-
tantly, the oral cavity plays a significant role in seeding the lower respiratory tract with diverse
microbes including Streptococcus spp., Prevotella spp., Veillonella spp., Fusobacterium spp.,
Rothia spp., and others (see Fig 1) [5,7,13]. Despite similar origins, the community structure of
lung samples and corresponding mouth wash samples are distinct, indicating that the lung
environment is unique from the upper respiratory tract and selects for a separate community
[21].
It is important to note that oral-associated microbes are detected in the airways of individu-
als with CF upon 16S rRNA gene deep sequence analysis of bronchoscopy-guided protected
brush samples (D.A. Hogan and A. Ashare, personal communication), which physically sepa-
rate the sample from contamination by the upper airways and oral cavity during sampling.
Thus, although it is possible, and even likely, that many lower airway samples (including spu-
tum) are partially contaminated by microbes in saliva during passage through the oral cavity,
oral-associated microbes are clearly prominent residents in the lower respiratory tract of
patients with CF.
Other body sites also play a role in the development of the microbial communities of CF air-
ways (see Fig 1). Nasal- and skin-associated microbes (such as S. aureus and Corynebacterium
spp.) can colonize early in life and, in some patients, persist through adulthood [3,5]. Addition-
ally, particularly in infants and young children, gut colonization with specific genera (including
Escherichia, Enterococcus, and others) may precede colonization in the airways, either via direct
or indirect interactions with the airways [3]. Furthermore, gut microbiota are central to train-
ing the immune system in young children—an event that is described as later impacting
immune modulation in the lungs [22] and, thus, may guide which species successfully colonize
and persist in the CF airway.
For some species, patient-to-patient transmission and the environment are primary sources
of infection, rather than the patient’s own microbiota. The common adulthood pathogens P.
aeruginosa and B. cepacia complex are typical soil bacteria and are most frequently acquired
from environmental reservoirs [8]. However, some strains of Burkholderia spp., as well as non-
tuberculous mycobacterium, may also be spread among patients, potentially to the extent of
becoming epidemic strains within the CF patient population—a particular concern for infec-
tion control [8]. Exemplary of these environmental and patient reservoirs, the lung microbiota
of co-inhabiting pediatric siblings is more similar than patients living separately [23].
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The Impact of Antibiotic Treatment on Community Composition
and Patient Outcome Is Complex and Not Well Understood
Throughout their lives, patients with CF receive antibiotic treatment both intermittently, for
chronic infection management, and aggressively, during hospitalization for pulmonary exacer-
bation. Despite this long-term exposure to a range of antimicrobial agents, microbiota of the
CF lung are not cleared, as would be expected with other common bacterial infections. Viable
bacterial cell counts generally only fall approximately 10-fold in sputum after antibiotic treat-
ment for pulmonary exacerbation [20], and the impact of antibiotics on total airway bacterial
populations is unknown. Molecular analyses of viable bacterial populations reveal decreased
microbial diversity within 72 hours of initiating treatment [24]; however, the impact of antibi-
otic treatment is transient, and baseline communities generally recover within 30 days [5].
Not surprisingly, bacteria acquire multi-drug resistance, and microbial biology and CF lung
physiology may further contribute to antibiotic tolerance. Low oxygen environments or growth
in a biofilm may enhance antibiotic tolerance [19]. This multifactorial contribution toward
high tolerance to antibiotics may in part explain the persistence of microbial communities in
the airways of patients with CF despite decades of ongoing antibiotic therapy.
Despite our limited understanding of the mechanism of action, patients treated with combi-
nation antibiotics during hospitalization report “feeling better” and show signs of clinical
improvement and increased lung function. Paradoxically, antibiotic treatment results in
decreased microbial diversity short-term, a trait usually associated with decreased health
[5,24]. In adults, decreased diversity over time correlates with progressive lung disease and
decreased lung function [5,25]. While clinical correlations have been observed between
decreased microbial diversity and poorer patient status, the causative factor(s) (such as absence
of a specific beneficial microbe, multiple beneficial microbes, a key microbial function carried
out by a subset or community of individuals, the host response to such communities, or others)
of this phenomenon are not known. Methods of promoting microbial diversity in the airways
have been proposed, ranging from decreased use of antibiotics to the enhanced use of prebio-
tics and probiotics; however, these approaches remain largely unexplored through clinical tri-
als. Ultimately, the optimal balance between aggressively treating patients during pulmonary
exacerbation and supporting clinical stability through maintenance therapy (both of which
undoubtedly contribute to extended patient life span) versus minimizing the decline in micro-
bial diversity remains a topic for debate.
The MoreWe Learn, the LessWe Understand about Why Patients
Get Sick (andWhat Makes Them Better)
Throughout life, patients experience periodic pulmonary exacerbations characterized as flares
of decreased lung function, increased cough and inflammation, chest pain, and often weight
loss. Historically, it was speculated that pathogen blooms or increased total bacterial load are
responsible for triggering these acute episodes. However, several recent independent studies
have demonstrated that overall bacterial abundance, community composition, and diversity
are largely unchanged when comparing paired samples from patients during clinical stability
and onset of exacerbation (before antibiotic treatment; [5] and others). Furthermore, neither
total viable cell counts nor P. aeruginosa viable counts are consistently altered during an
exacerbation [20].
Despite broad measures of community dynamics often remaining unchanged in patients
treated with antibiotics, changes in immune response, such as increased inflammation, suggest
altered host—pathogen interactions resulting from biological changes we may be missing. For
example, the increased abundance of Streptococcusmilleri group, until recently not associated
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with CF exacerbation, may contribute to pulmonary exacerbation [14]. Changes in unlikely
pathogens, such as increased abundance of Gemella spp., may serve as biomarkers of clinical
worsening [26]. Additionally, viruses, especially influenza A, have been correlated with more
severe symptoms during an exacerbation [2,8].
Alternatively, while the community structure may not change during exacerbation, biologi-
cal functions might; changes in microbial gene expression, virulence, or metabolite production
may alter disease course. For example, in a study by Twomey and colleagues, enhanced
accumulation of metabolites associated with anaerobic metabolism, including lactate and
putrescine, were observed to correlate with the exacerbation state [27]. Overall, our current
understanding of functional community changes during states of stability versus disease is lim-
ited. However, the development of new methodologies and affordable, high-throughput tech-
nologies in the areas of metagenomics, metatranscriptomics, and metabolomics is quickly
providing the tools needed to investigate these outstanding questions.
Lower airway inflammation is a hallmark of patients with CF and increases with age and dis-
ease progression [28]; however, the host immune response is not uniform toward all microbes.
For example, some viral infections of the lower respiratory tract (respiratory syncytial virus
and influenza A, in particular) are associated with an even further elevated proinflammatory
response and neutrophil influx [10]. Meanwhile, allergic bronchopulmonary aspergillosus, a
clinical condition caused by immune sensitization to Aspergillus fumigatus antigens that devel-
ops in 4%–15% of patients with CF, is associated with enhanced type 2 T-helper cells [29].
These are just two examples within a breadth of differential host responses delivered against the
complex polymicrobial infections in CF airways. Identification and determination of the molec-
ular mechanism behind a multitude of different host responses engaged during stability versus
exacerbation may provide novel biomarkers for monitoring patient infection status and guiding
targeted treatment strategies.
The keys to optimal patient treatment are not clear. While we now recognize the importance
of the polymicrobial nature of CF lung infections, we have a long way to go to understand how
such communities, and the host’s response to those communities, contribute to disease. Con-
ventional culture-based methods of diagnosing infections and determining antibiotic suscepti-
bilities are expensive yet yield limited information about the composition and function of these
polymicrobial infections, while drug susceptibility profiles provide minimal correlation with
clinical outcome [30]. In the near future, embracing new diagnostic methods in the clinic,
including utilization of rapidly advancing molecular-based methods, identifying biological
markers of disease progression, establishing the impact of polymicrobial infection on host and
treatment outcome, and tailoring treatment patient-by-patient will be essential in proactively
treating and delaying clinical worsening.
Conclusions
With the explosion of 16S rRNA gene deep sequencing studies performed over the past few
years analyzing the microbial populations in the airways of CF patients, we face a new chal-
lenge: what does it mean? To begin to understand the impact of these polymicrobial infections
on disease progression, we must study not only their composition but also their dynamics,
the effects of inter-microbial and host—microbe interactions, the role of diverse host factors
(e.g., genetics, immune response, and environment), and the impact of clinical intervention.
Researchers are just beginning to tackle these issues. Most importantly, upon elucidation of
complex, multifactorial disease mechanisms impacting CF lung infections, the ultimate chal-
lenge will be to use this information to develop new therapeutics, personalize care, and opti-
mize treatment strategies.
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